Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Accounts Payables (2016 - 2024)

Historic Accounts Payables for Sanofi (SNY) over the last 17 years, with Q2 2025 value amounting to $8.0 billion.

  • Sanofi's Accounts Payables rose 5.13% to $8.0 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $8.0 billion, marking a year-over-year increase of 5.13%. This contributed to the annual value of $8.1 billion for FY2024, which is 179.31% up from last year.
  • Latest data reveals that Sanofi reported Accounts Payables of $8.0 billion as of Q2 2025, which was up 5.13% from $8.1 billion recorded in Q4 2024.
  • In the past 5 years, Sanofi's Accounts Payables registered a high of $8.1 billion during Q4 2024, and its lowest value of $6.5 billion during Q2 2021.
  • Its 5-year average for Accounts Payables is $7.5 billion, with a median of $7.9 billion in 2023.
  • In the last 5 years, Sanofi's Accounts Payables skyrocketed by 1942.31% in 2021 and then tumbled by 168.04% in 2022.
  • Quarter analysis of 5 years shows Sanofi's Accounts Payables stood at $7.1 billion in 2021, then dropped by 1.68% to $7.0 billion in 2022, then grew by 13.43% to $7.9 billion in 2023, then increased by 2.34% to $8.1 billion in 2024, then dropped by 0.75% to $8.0 billion in 2025.
  • Its Accounts Payables stands at $8.0 billion for Q2 2025, versus $8.1 billion for Q4 2024 and $8.0 billion for Q2 2024.